

Supplemental Table 1. *MTBP* is commonly co-amplified with *MYC* in multiple human cancers

Cancer ^a	Sample #	<i>MTBP</i> amp ^b	<i>MYC</i> amp ^b	<i>MYC</i> and <i>MTBP</i> co-amp ^b	<i>MTBP</i> amp in <i>MYC</i> amp ^{b,c}	Significance ^d
Ovarian Serous Cystadenocarcinoma	569	32.2% (183)	42.0% (239)	31.1% (177)	74.1% (177/239)	p < 0.0001
Breast Invasive Carcinoma	913	18.7% (171)	21.9% (200)	18.6% (170)	85.0% (170/200)	p < 0.0001
Hepatocellular Carcinoma	97	19.6% (19)	20.6% (20)	18.6% (18)	90.0% (18/20)	p < 0.0001
Prostate Adenocarcinoma	187	8.6% (16)	10.2% (19)	8.6% (16)	84.2% (16/19)	p < 0.0001
Head & Neck Squamous Cell Carcinoma	306	8.2% (25)	11.8% (36)	7.8% (24)	66.7% (24/36)	p < 0.0001
Stomach Adenocarcinoma	306	6.9% (21)	10.5% (32)	6.9% (21)	65.6% (21/32)	p < 0.0001
Glioma, Lower Grade	220	6.8% (15)	7.3% (16)	6.8% (15)	93.8% (15/16)	p < 0.0001
Lung Adenocarcinoma	230	7.0% (16)	9.1% (21)	6.1% (14)	66.7% (14/21)	p < 0.0001
Urothelial Carcinoma	150	6.7% (10)	9.3% (14)	6.0% (9)	64.3% (9/14)	p < 0.0001
Cutaneous Melanoma	244	5.3% (13)	5.7% (14)	5.3% (13)	92.9% (13/14)	p < 0.0001
Colon and Rectum Adenocarcinoma	575	4.7% (27)	6.3% (36)	4.5% (26)	72.2% (26/36)	p < 0.0001
Adenoid Cystic Carcinoma	60	3.3% (2)	5.0% (3)	3.3% (2)	66.7% (2/3)	p = 0.0017
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	126	4.0% (5)	7.9% (10)	3.2% (4)	40.0% (4/10)	p = 0.0001
Renal Chromophobe Carcinoma	66	3.0% (2)	3.0% (2)	3.0% (2)	100% (2/2)	p < 0.0001
Soft Tissue Sarcoma	207	3.4% (7)	3.4% (7)	2.9% (6)	85.7% (6/7)	p < 0.0001
Uterine Corpus Endometrioid Carcinoma	363	3.0% (11)	8.0% (29)	2.8% (10)	34.5% (10/29)	p < 0.0001
Glioblastoma Multiforme	497	1.8% (9)	2.0% (10)	1.4% (7)	70.0% (7/10)	p < 0.0001
Renal Clear Cell Carcinoma	436	0.9% (4)	0.9% (4)	0.9% (4)	100% (4/4)	p < 0.0001
Lung Squamous Cell Carcinoma	179	0.6% (1)	4.5% (8)	0.6% (1)	12.5% (1/8)	p = 0.0447
Acute Myeloid Leukemia	191	0.5% (1)	0.5% (1)	0.5% (1)	100% (1/1)	p = 0.0052

^aGene copy number gains in *MTBP* and/or *MYC* in human cancers in TCGA from the cBioPortal for Cancer Genomics obtained June 2013.

^bPercentage of tumors with the indicated amplification and in parentheses, the number of samples

^cThe percentage of tumors with *MTBP* amplified in cancers that had amplified *MYC*.

^dSignificance for *MYC* and *MTBP* co-amplification calculated using a two-tailed Fisher's exact test.